The changing landscape of clinical trials in Asia and the Pacific Rim

Tuesday, December 1, 2015

In recent years, the clinical trial landscape in Asia and the Pacific Rim has evolved faster than in most other regions. More than half of the world’s population lives in this rapidly developing area, which includes advanced economies such as Australia, Singapore and South Korea, as well as countries with vast populations like India and China.

[Read More]

Parexel, Kyoto ink agreement for Japan’s biopharmaceutical workforce

Friday, November 13, 2015

Parexel International, a global biopharmaceutical services provider, and Kyoto Pharmaceutical University (KPU), a private pharmacy and science university, have announced a new joint program for clinical research and clinical trial management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry.

[Read More]

Hepalink to acquire Cytovance

Wednesday, August 26, 2015

Hepalink USA, a China-based global supplier of heparin sodium API, has entered into a definitive agreement to acquire Cytovance Biologics, a biopharmaceutical contract development manufacturing (CDMO) company, for $205.68 million in cash plus certain contingent payments.

[Read More]

China to reform drug approval system

Thursday, August 20, 2015

China has decided to reform its appraisal and approval system for drugs and medical instruments with the aim of improving drug safety and quality and encouraging innovation.

[Read More]

First made-in-Singapore cancer drug enters clinical testing

Thursday, July 23, 2015

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. The Agency for Science, Technology and Research (A*STAR) and Duke-National University of Singapore Graduate Medical School (Duke-NUS) have announced the start of a phase I clinical trial of novel cancer drug candidate, ETC-159.

[Read More]